Robert L. Dood
( out of 123 reviews )

Robert L. Dood, MD, MSCE

Languages spoken: English, Spanish

Clinical Locations

Sugar House Health Center

Salt Lake City
801-581-2000

  • Robert Dood, MD MSCE is a gynecologic oncologist and assistant professor at the University of Utah School of Medicine and the Huntsman Cancer Institute. He specializes in the treatment of gynecologic pre-cancers and cancers of the ovary, uterus and endometrium, cervix, vulva, and vagina. His interests include screening and managing high risk and hereditary cancer populations including those with BRCA mutations and Lynch/HNPCC syndromes. He has a passion for fertility-sparing approaches in young women with cancer, pre-cancer, and hereditary syndromes, with special skills in hormonal approaches to endometrial cancer, uterus-sparing surgery for cervix cancer (trachelectomy), and sentinel lymph node evaluation of cervix and uterine cancers. His surgical expertise includes personalized approaches to cancer care, and minimally invasive approaches including both laparoscopic and robotic technologies.

    His research interests include implementing enhanced recovery after surgery (ERAS) protocols, optimizing clinical and surgical outcomes, efficient survivorship models, with methods in implementation science and big data.

    After completing his Bachelor of Science (BS) degree in Biochemistry from the University of Michigan with High Distinction, he attended the Perelman School of Medicine at the University of Pennsylvania where he received his Medical Doctorate (MD) and Master of Science in Clinical Epidemiology (MSCE) degrees. He completed his residency in Obstetrics and Gynecology at the Hospital of the University of Pennsylvania, and his research and clinical fellowship in Gynecologic Oncology at the University of Texas MD Anderson Cancer Center.

    Specialties

    Patient Rating

    4.9 /5
    ( out of 123 reviews )

    The patient rating score is an average of all responses on our patient experience survey. The rating averages scores for all questions about care from our providers.

    The scale on which responses are measured is 1 to 5 with 5 being the best score.

    Patient Comments

    Patient comments are gathered from our patient experience survey and displayed in their entirety.
    Patients are de-identified for confidentiality and patient privacy.

    February 23, 2024
    HUNTSMAN CANCER CENTER

    I feel his care and he has been a great advocate in getting my care in a timely manner

    February 07, 2024
    SUGAR HOUSE HEALTH CENTER

    good doctor

    February 07, 2024
    HUNTSMAN CANCER CENTER

    Dr Dood is genuinely caring about his patients, he involves them throughout the entire process and makes sure there is 100% understanding

    February 07, 2024
    HUNTSMAN CANCER CENTER

    Dr. Dood is the most caring Doctor I have seen in my 79 years on this earth. He is very knowledgeable in his field. He gives me hope, but is always honest in my treatment and prognosis. I am so thankful to have Dr. Dood as my physician.

    February 02, 2024
    SUGAR HOUSE HEALTH CENTER

    He¿s wonderful, I would highly recommend him!

    January 18, 2024
    HUNTSMAN CANCER CENTER

    Very compassionate an tell your like iit is.

    January 11, 2024
    SUGAR HOUSE HEALTH CENTER

    I love Dr. Dood!

    January 08, 2024
    SUGAR HOUSE HEALTH CENTER

    Dr Dood is excellent. He is a professional, compassionate and sensitive. He is a good listener, welcomes questions and respects my decisions regarding treatment. We have complete trust in his care.

    January 05, 2024
    SUGAR HOUSE HEALTH CENTER

    I felt like he was interested in getting me the best care for my situation. I only wish we could go on to the next step. Waiting is so hard.

    See More Patient Comments

  • Robert Dood, MD MSCE is a gynecologic oncologist and assistant professor at the University of Utah School of Medicine and the Huntsman Cancer Institute. He specializes in the treatment of gynecologic pre-cancers and cancers of the ovary, uterus and endometrium, cervix, vulva, and vagina. His interests include screening and managing high risk and hereditary cancer populations including those with BRCA mutations and Lynch/HNPCC syndromes. He has a passion for fertility-sparing approaches in young women with cancer, pre-cancer, and hereditary syndromes, with special skills in hormonal approaches to endometrial cancer, uterus-sparing surgery for cervix cancer (trachelectomy), and sentinel lymph node evaluation of cervix and uterine cancers. His surgical expertise includes personalized approaches to cancer care, and minimally invasive approaches including both laparoscopic and robotic technologies.

    His research interests include implementing enhanced recovery after surgery (ERAS) protocols, optimizing clinical and surgical outcomes, efficient survivorship models, with methods in implementation science and big data.

    After completing his Bachelor of Science (BS) degree in Biochemistry from the University of Michigan with High Distinction, he attended the Perelman School of Medicine at the University of Pennsylvania where he received his Medical Doctorate (MD) and Master of Science in Clinical Epidemiology (MSCE) degrees. He completed his residency in Obstetrics and Gynecology at the Hospital of the University of Pennsylvania, and his research and clinical fellowship in Gynecologic Oncology at the University of Texas MD Anderson Cancer Center.

    Board Certification and Academic Information

    Academic Departments Obstetrics & Gynecology -Primary
    Academic Divisions Gynecological Oncology

    Selected Publications

    Journal Article

    1. Dood RL, Zhao Y, Armbruster SD, Coleman RL, Tworoger S, Sood AK, Baggerly KA (2018). Defining Survivorship Trajectories Across Patients with Solid Tumors: An Evidence-Based Approach. JAMA Oncol, 4(11), 1519-1526. (Read full article)
    2. Dood RL, Fleming ND, Coleman RL, Westin SN, Lara OD, LaFargue CJ, Liu J, Sood AK (2018). When Ovarian Cancer Is Not: Characterizing Nonovarian Cancer Pathology in a Laparoscopy-Based Triage System. Int J Gynecol Cancer, 28(8), 1485-1490. (Read full article)
    3. Nagaraja AS, Dood RL, Armaiz-Pena G, Kang Y, Wu SY, Allen JK, Jennings NB, Mangala LS, Pradeep S, Lyons Y, Haemmerle M, Gharpure KM, Sadaoui NC, Rodriguez-Aguayo C, Ivan C, Wang Y, Baggerly K, Ram P, Lopez-Berestein G, Liu J, Mok SC, Cohen L, Lutgendorf SK, Cole SW, Sood AK (2018). Adrenergic-mediated increases in INHBA drive CAF phenotype and collagens. JCI Insight, 3(11). (Read full article)
    4. Huang Y, Hu W, Huang J, Shen F, Sun Y, Ivan C, Pradeep S, Dood R, Haemmerle M, Jiang D, Mangala LS, Noh K, Hansen JM, Dalton HJ, Previs RA, Nagaraja AS, McGuire M, Jennings NB, Broaddus R, Coleman RL, Sood AK (2017). Inhibiting Nuclear Phospho-Progesterone Receptor Enhances Antitumor Activity of Onapristone in Uterine Cancer. Mol Cancer Ther, 17(2), 464-473. (Read full article)
    5. Lyons YA, Pradeep S, Wu SY, Haemmerle M, Hansen JM, Wagner MJ, Villar-Prados A, Nagaraja AS, Dood RL, Previs RA, Hu W, Zhao Y, Mak DH, Xiao Z, Melendez BD, Lizee GA, Mercado-Uribe I, Baggerly KA, Hwu P, Liu J, Overwijk WW, Coleman RL, Sood AK (2017). Macrophage depletion through colony stimulating factor 1 receptor pathway blockade overcomes adaptive resistance to anti-VEGF therapy. Oncotarget, 8(57), 96496-96505. (Read full article)
    6. Haemmerle M, Taylor ML, Gutschner T, Pradeep S, Cho MS, Sheng J, Lyons YM, Nagaraja AS, Dood RL, Wen Y, Mangala LS, Hansen JM, Rupaimoole R, Gharpure KM, Rodriguez-Aguayo C, Yim SY, Lee JS, Ivan C, Hu W, Lopez-Berestein G, Wong ST, Karlan BY, Levine DA, Liu J, Afshar-Kharghan V, Sood AK (2017). Platelets reduce anoikis and promote metastasis by activating YAP1 signaling. Nat Commun, 8(1), 310. (Read full article)
    7. Nagaraja AS, Dood RL, Armaiz-Pena G, Kang Y, Wu SY, Allen JK, Jennings NB, Mangala LS, Pradeep S, Lyons Y, Haemmerle M, Gharpure KM, Sadaoui NC, Rodriguez-Aguayo C, Ivan C, Wang Y, Baggerly K, Ram P, Lopez-Berestein G, Liu J, Mok SC, Cohen L, Lutgendorf SK, Cole SW, Sood AK (2017). Adrenergic-mediated increases in INHBA drive CAF phenotype and collagens. JCI Insight, 2(16). (Read full article)
    8. Sans M, Gharpure K, Tibshirani R, Zhang J, Liang L, Liu J, Young JH, Dood RL, Sood AK, Eberlin LS (2017). Metabolic Markers and Statistical Prediction of Serous Ovarian Cancer Aggressiveness by Ambient Ionization Mass Spectrometry Imaging. Cancer Res, 77(11), 2903-2913. (Read full article)
    9. Dood RL, Gracia CR, Sammel MD, Haynes K, Senapati S, Strom BL (2014). Endometrial cancer after endometrial ablation vs medical management of abnormal uterine bleeding. J Minim Invasive Gynecol, 21(5), 744-52. (Read full article)

    Letter

    1. Dood RL (2014). Reply: To PMID 24590007. [Letter to the editor]. J Minim Invasive Gynecol, 22(3), 510. (Read full article)

  • News & Podcasts